Addicted to proteostasis: How KRAS-driven cancers acquire resistance to clinical KRAS inhibitors

Cell Chem Biol. 2023 Nov 16;30(11):1334-1336. doi: 10.1016/j.chembiol.2023.10.007.

Abstract

The development of KRAS inhibitors was a remarkable feat, yet their efficacy is limited by inevitable resistance. In the September issue of Science, Lv et al.1 demonstrate how KRAS-driven cancers rewire signaling to restore protein homeostasis and acquire resistance to KRAS inhibitors with implications for novel combination therapeutic strategies.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Humans
  • Mutation
  • Neoplasms* / drug therapy
  • Protein Kinase Inhibitors / pharmacology
  • Protein Kinase Inhibitors / therapeutic use
  • Proteostasis*
  • Proto-Oncogene Proteins p21(ras) / genetics
  • Signal Transduction

Substances

  • Proto-Oncogene Proteins p21(ras)
  • Protein Kinase Inhibitors
  • KRAS protein, human